You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大摩對中資醫藥、研發、醫療設備、分銷及中藥股投資評級及目標價(表)
摩根士丹利發表研究報告,對中資醫藥、研發、醫療設備、分銷及中藥股投資評級及目標價表列如下: 股份?投資評級?目標價(港元) 首選股 恆端醫藥(600276.SH)?增持?72元人民幣 信達生物(01801.HK)?增持?95元 藥明生物(02269.HK)?增持?175元 創新藥/生物醫藥股 和譽-B(02256.HK)?增持?13.6元 康方生物-B(09926.HK)?增持?68.6元 康寧傑瑞製藥-B(09966.HK)?增持?31.2元 騰盛博藥-B(02137.HK)?增持?50.27->46元 石藥集團(01093.HK)?增持?12元 基石藥業-B(02616.HK)?增持?20.5->10.9元 北海康成-B(01228.HK)?增持?11元 雲頂新耀-B(01952.HK)?增持?96.2元 翰森製藥(03692.HK)?增持?38.7->33.6元 和鉑醫藥-B(02142.HK)?增持?13.9元 和黃醫藥(HCM.US)?增持?40.3->46.3美元 諾誠健華-B(09969.HK)?增持?35.3元 康諾亞-B(02162.HK)?增持?74.8元 李氏大藥廠(00950.HK)?增持->與大市同步?6->4.1元 歐康維視生物-B(01477.HK)?增持?33.5元 榮昌生物-B(09995.HK)?增持?134.1元 先聲藥業(02096.HK)?增持?11.5元 中生製藥(01177.HK)?增持?10元 三生製藥(01530.HK)?與大市同步?8.5元 歌禮制藥-B(01672.HK)?與大市同步->減持?2.8->2.6元 研發 藥明康德(02359.HK)?增持?211元 醫療設備 先瑞達醫療-B(06669.HK)?增持?25元 微創醫療(00853.HK)?增持?53元 沛嘉醫療-B(09996.HK)?增持?30元 威高股份(01066.HK)?與大市同步?17.3元 歸創通橋-B(02190.HK)?增持?58元 醫院股 海吉亞(06078.HK)?增持?90元 錦欣生殖(01951.HK)?增持?18->12.4元 華潤醫療(01515.HK)?與大市同步?7.55->5.5元 雍禾醫療(02279.HK)?增持?17元 線上保健股 阿裏健康(00241.HK)?增持?13元 平安好醫生(01833.HK)?與大市同步?43元 分銷商 上海醫藥(02607.HK)?增持?20.8元 國藥控股(01099.HK)?與大市同步?21元 華潤醫藥(03320.HK)?與大市同步?5.5元 製藥股 康哲藥業(00867.HK)?增持?22元 賽生藥業(06600.HK)?增持?18.8元 石四藥(02005.HK)?增持?6.5元 復星醫藥(02196.HK)?與大市同步?54元 東陽光藥(01558.HK)?與大市同步?7元 聯邦製藥(03933.HK)?與大市同步?6.8元 麗珠醫藥(01513.HK)?減持?22.6元 綠葉製藥(02186.HK)?減持?3.6元 原料藥股 海普瑞(09989.HK)?增持?14.2元 中藥股 同仁堂國藥(03613.HK)?增持?16.5元 中國中藥(00570.HK)?增持?6.3元 白雲山(00874.HK)?與大市同步?23.5元 神威藥業(02877.HK)?與大市同步?7.9元 同仁堂科技(01666.HK)?與大市同步?6.9元
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account